Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Target Oncol · 2019 · PMC6602986 · PMID 31124059

Europe PMC DOI

hedged sentence

0.1060

closest p · 2.1× alpha

0.1060

boldest claim

The sentences

showed a trendp = 0.106not close (p > 0.1)

Upon progressive disease, 20 patients (30.8%) received subsequent chemotherapy, and showed a trend for longer median overall survival (OS) than in those receiving a non-chemotherapy regimen (25.0 vs. 11.8 months, p = 0.106).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.